Las Vegas, NV -- (SBWIRE) -- 12/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Cereplast Inc (OTCMKTS:CERP), FuelCell Energy Inc (NASDAQ:FCEL), EnteroMedics Inc (NASDAQ:ETRM), Amarin Corporation plc (ADR) (NASDAQ:AMRN)
Cereplast Inc (OTCMKTS:CERP) managed to keep its fall at -6.74% on below -normal volume of 11.87M shares. The stock settled at $0.00083 after floating in a range of $0.01 to $0.01. Its latest price has reached market capitalization of $5.98 million. Its 52-week range has been $0.01 to $0.09. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line).
Has CERP Found The Bottom and Ready To Move Up? Find Out Here
FuelCell Energy Inc (NASDAQ:FCEL) traded up on a volume of 9.87 million, higher than its standard daily volume. Shares have gained 9.82% to $1.51. Over the last twelve months, the stock has gained 75.58% and faced a worst price of $0.84. FuelCell Energy, Inc. (FuelCell Energy) is a integrated fuel cell company. The Company designs, manufactures, sells, installs, operates and service ultra-clean, stationary fuel cell power plants for distributed baseload power generation.
For How Long FCEL’s Gloss will Attract Investors? Find out via this report
EnteroMedics Inc (NASDAQ:ETRM) settled -13.39% lower at $1.94 on above-normal volume of 9.33M shares during the last trading day. The stock has its 12-month high at $3.23 and 52-week low price was $0.81. It traded in a range of $1.87 to $2.18 during the last trading day. EnteroMedics Inc. (EnteroMedics) is a development- stage medical device company. The Company focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Will ETRM Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Amarin Corporation plc (ADR) (NASDAQ:AMRN) was down on low volume, trading at a volume of 6.47M versus its average daily volume of 6.68 million shares. At $1.94, the stock has attained market capitalization of 334.84 million. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011.
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)